1. Generics Bulletin
  2. >>Products

‘Significant Discounts’ For Biosimilars Could Disrupt US Market

Pacific Research Institute Report Urges Removal Of Barriers To Price Competition

 
• By Dave Wallace

With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.

Money Dollar Note Disruption Concept
Reforms to the rebate system could allow lower-priced biosimilars to capture greater market share, Winegarden believes • Source: Shutterstock

Reforms to prevent anti-competitive pricing practices for brand biologics and to change the way formularies work are essential to allow biosimilar competition to further flourish in the US, according to Wayne Winegarden, senior fellow in business and economics at free-market thinktank the Pacific Research Institute and director of the PRI’s Center for Medical Economics and Innovation.

Speaking as the PRI published a new report authored by Winegarden titled “Falling Prices: Biosimilar competition has saved billions of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products